Literature DB >> 23239091

Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani.

Arpita Kulshrestha1, Vasundhra Bhandari, Rupkatha Mukhopadhyay, V Ramesh, Shyam Sundar, Louis Maes, Jean Claude Dujardin, Syamal Roy, Poonam Salotra.   

Abstract

Simple, cost-effective approach for routine surveillance of parasite susceptibility to antileishmanial drug miltefosine (MIL) is highly desirable for controlling emergence of drug resistance in visceral leishmaniasis (VL). We validated a simple resazurin-based fluorimetric assay using promastigotes to track natural MIL tolerance in Leishmania donovani parasites from VL cases (n = 17) against standard amastigote assay, in two different labs in India. The inter-stage MIL susceptibility correlated strongly (r = 0.70, p = 0.0018) using J774.A.1 macrophage cell line-based amastigote assay and fluorescence-based resazurin assay for promastigotes. Investigation of inter-stage MIL susceptibility for the same set of clinical isolates in another lab also showed a strong correlation (r = 0.72, p = 0.0012) using mouse peritoneal macrophages for amastigote assay and resazurin-based alamar blue assay for promastigotes. Additionally, parasites from post-kala-azar dermal leishmaniasis (PKDL) lesions (n = 7, r = 0.78, p = 0.046) and MIL-induced parasites (r = 0.92, p = 0.0001; n = 3) also exhibited a strongly correlated inter-stage miltefosine susceptibility. Thus, our results support the utility of resazurin assay as a simplified biological tool for MIL susceptibility monitoring in clinical isolates from MIL-treated VL/PKDL patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23239091     DOI: 10.1007/s00436-012-3212-3

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  17 in total

Review 1.  Advances in leishmaniasis.

Authors:  Henry W Murray; Jonathan D Berman; Clive R Davies; Nancy G Saravia
Journal:  Lancet       Date:  2005 Oct 29-Nov 4       Impact factor: 79.321

2.  In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity.

Authors:  Dhiraj Kumar; Arpita Kulshrestha; Ruchi Singh; Poonam Salotra
Journal:  Antimicrob Agents Chemother       Date:  2008-11-17       Impact factor: 5.191

3.  Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis.

Authors:  V Ramesh; G K Katara; S Verma; P Salotra
Journal:  Br J Dermatol       Date:  2011-08       Impact factor: 9.302

4.  Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani.

Authors:  R Lira; S Sundar; A Makharia; R Kenney; A Gam; E Saraiva; D Sacks
Journal:  J Infect Dis       Date:  1999-08       Impact factor: 5.226

Review 5.  Post-kala-azar dermal leishmaniasis.

Authors:  V Ramesh; A Mukherjee
Journal:  Int J Dermatol       Date:  1995-02       Impact factor: 2.736

Review 6.  Visceral leishmaniasis control: a public health perspective.

Authors:  M Boelaert; B Criel; J Leeuwenburg; W Van Damme; D Le Ray; P Van der Stuyft
Journal:  Trans R Soc Trop Med Hyg       Date:  2000 Sep-Oct       Impact factor: 2.184

7.  A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye Alamar Blue.

Authors:  J Mikus; D Steverding
Journal:  Parasitol Int       Date:  2000-01       Impact factor: 2.230

8.  In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent.

Authors:  Karin Seifert; Patricia Escobar; Simon L Croft
Journal:  J Antimicrob Chemother       Date:  2010-01-20       Impact factor: 5.790

9.  In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences.

Authors:  Marieke Vermeersch; Raquel Inocêncio da Luz; Kim Toté; Jean-Pierre Timmermans; Paul Cos; Louis Maes
Journal:  Antimicrob Agents Chemother       Date:  2009-06-22       Impact factor: 5.191

10.  Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine).

Authors:  Karin Seifert; Sangeeta Matu; F Javier Pérez-Victoria; Santiago Castanys; Francisco Gamarro; Simon L Croft
Journal:  Int J Antimicrob Agents       Date:  2003-10       Impact factor: 5.283

View more
  17 in total

1.  In vitro susceptibility of Leishmania donovani to miltefosine in Indian visceral leishmaniasis.

Authors:  Vijay Kumar Prajapati; Smriti Sharma; Madhukar Rai; Bart Ostyn; Poonam Salotra; Manu Vanaerschot; Jean-Claude Dujardin; Shyam Sundar
Journal:  Am J Trop Med Hyg       Date:  2013-08-26       Impact factor: 2.345

Review 2.  Susceptibility Testing of Medically Important Parasites.

Authors:  Abebe Genetu Bayih; Anjan Debnath; Edward Mitre; Christopher D Huston; Benoît Laleu; Didier Leroy; Benjamin Blasco; Brice Campo; Timothy N C Wells; Paul A Willis; Peter Sjö; Wesley C Van Voorhis; Dylan R Pillai
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

3.  Experimental selection of paromomycin and miltefosine resistance in intracellular amastigotes of Leishmania donovani and L. infantum.

Authors:  S Hendrickx; G Boulet; A Mondelaers; J C Dujardin; S Rijal; L Lachaud; P Cos; P Delputte; L Maes
Journal:  Parasitol Res       Date:  2014-03-11       Impact factor: 2.289

4.  Susceptibility of promastigotes and intracellular amastigotes from distinct Leishmania species to the calpain inhibitor MDL28170.

Authors:  Pedro Soares de Sousa Araújo; Simone Santiago Carvalho de Oliveira; Claudia Masini d'Avila-Levy; André Luis Souza Dos Santos; Marta Helena Branquinha
Journal:  Parasitol Res       Date:  2018-05-04       Impact factor: 2.289

5.  Effect of Itraconazole-Ezetimibe-Miltefosine Ternary Therapy in Murine Visceral Leishmaniasis.

Authors:  Valter V Andrade-Neto; Karina M Rebello; Thais M Pereira; Eduardo Caio Torres-Santos
Journal:  Antimicrob Agents Chemother       Date:  2021-02-22       Impact factor: 5.191

6.  Lipase Precursor-Like Protein Promotes Miltefosine Tolerance in Leishmania donovani by Enhancing Parasite Infectivity and Eliciting Anti-inflammatory Responses in Host Macrophages.

Authors:  Deepak Kumar Deep; Ruchi Singh; Arpita Kulshrestha; Saima Wajid; Poonam Salotra
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

7.  Cyclobenzaprine Raises ROS Levels in Leishmania infantum and Reduces Parasite Burden in Infected Mice.

Authors:  Edézio Ferreira Cunha-Júnior; Valter Viana Andrade-Neto; Marta Lopes Lima; Thais Alves da Costa-Silva; Andres J Galisteo Junior; Maria A Abengózar; Coral Barbas; Luis Rivas; Elmo Eduardo Almeida-Amaral; Andre Gustavo Tempone; Eduardo Caio Torres-Santos
Journal:  PLoS Negl Trop Dis       Date:  2017-01-03

8.  Achievement of constitutive fluorescent pLEXSY-egfp Leishmania braziliensis and its application as an alternative method for drug screening in vitro.

Authors:  Matheus Silva E Bastos; Luciana Ângelo de Souza; Thiago Souza Onofre; Abelardo Silva; Márcia Rogéria de Almeida; Gustavo Costa Bressan; Juliana Lopes Rangel Fietto
Journal:  Mem Inst Oswaldo Cruz       Date:  2017-02       Impact factor: 2.743

9.  Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain.

Authors:  Keshav Rai; Bart Cuypers; Narayan Raj Bhattarai; Surendra Uranw; Maya Berg; Bart Ostyn; Jean-Claude Dujardin; Suman Rijal; Manu Vanaerschot
Journal:  MBio       Date:  2013-10-08       Impact factor: 7.867

10.  Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India.

Authors:  V Ramesh; Ruchi Singh; Kumar Avishek; Aditya Verma; Deepak Kumar Deep; Sandeep Verma; Poonam Salotra
Journal:  PLoS Negl Trop Dis       Date:  2015-10-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.